Press release
UK IBD market is estimated to grow significantly at a CAGR of around 4.7% during the forecast period.
UK IBD market is estimated to grow significantly at a CAGR of around 4.7% during the forecast period. IBD is one of the key chronic inflammatory digestive diseases prevalent in the country. The disease is caused by a number of factors including the changing lifestyle of the population, the prevalence of Crohn's disease in the country are a few of the key reasons which are expected to promote the demand of treatment and diagnostic services for IBD. The research on autoimmune diseases has gained momentum in the UK.Request a Free Sample of our Report on UK Inflammatory Bowel Disease Market: https://www.omrglobal.com/request-sample/uk-ibd-inflammatory-bowel-disease-market
Although the inflammatory and immune diseases register only a small portion in the research funding by the public, it is expected to increase in the coming years. For instance, the department of health' National Institute of health research allocated a budget of $52.6 million in 2014-2015 for research on inflammatory and immune diseases. This budget also included research on inflammatory diseases in the country.
On similar lines, the medical research council also contributed $44.4 million for research on immunology. As these research funding increase in the coming years so as to decrease the mortality rate due to these chronic diseases, it is expected to further increase the opportunities for the market in the near future.
UK IBD market is segmented on the basis of disease type, diagnostics, and therapeutics. UK IBD market is segmented on the basis of disease type into ulcerative colitis and Crohn's disease. Crohn's disease segment is estimated to dominate the market. The growth of the segment is attributed to the comparatively higher incidence of Crohn's disease than ulcerative colitis.
On the basis of diagnostics, the market is segmented into blood and stool, endoscopies, ultrasound, and X-rays. Endoscopy is a conventional diagnostic method that is widely being used for the diagnosis of IBD and having a considerable share in the market. The therapeutics segment is further segmented into anti-inflammatory drugs and surgery. There is a range of anti-inflammatory drugs used for the treatment of IBD, such as immunosuppressants (methotrexate, ciclosporin, and azathioprine), steroids and biological drugs. These are usually the first step in the treatment of IBD.
A Full Report of UK Inflammatory Bowel Disease Market is Available at https://www.omrglobal.com/industry-reports/uk-ibd-inflammatory-bowel-disease-market
UK IBD Market Segmentation
By Disease Type
o Ulcerative Colitis
o Crohn's Disease
By Diagnostics
o Blood and Stool Tests
o Endoscopies,
o Ultrasound
o X-Ray
By Therapeutics
o Surgery
o Anti- Inflammatory Drug Administration
o Steroids
o Immunosuppressant
o Biological Drugs
o Amino salicylates
o Others
Company Profiles
o AbbVie Inc.
o Allergan, PLC
o Boehringer Ingelheim International GmbH
o Daiichi Sankyo Co. Ltd.
o Eli Lilly and Co.
o Johnson & Johnson Services Inc.
o Mercator Pharmaceutical Solutions
o Pfizer Inc.
o RPG Life Sciences Ltd.
o Sanofi S.A.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/uk-ibd-inflammatory-bowel-disease-market
For More Information, Visit https://www.omrglobal.com/
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +1 646-755-7667, +91 780-304-0404
About us:
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release UK IBD market is estimated to grow significantly at a CAGR of around 4.7% during the forecast period. here
News-ID: 1965901 • Views: …
More Releases from Orion Market Research
Healthcare Distribution Market Size, Trends, Latest Insights, Analysis and Forec …
Global healthcare distribution market is anticipated to grow at a CAGR of 6.7% during the forecast period (2024-2031). Globally, a considerable increase in the burden of chronic diseases pressuring countries to adopt effective and efficient distribution of healthcare products. Commonly prevailing chronic diseases include heart attacks and strokes, cancer such as breast and colon, diabetes, epilepsy and seizures, obesity, and oral health issues.
To learn more about this report request…
Prediabetes Market Size, Trends, Latest Insights, Analysis and Forecast 2024-203 …
Global prediabetes market is anticipated to grow at a CAGR of 7.2% during the forecast period (2024-2031). A major factor supporting the growth of the market is the increasing product expansion and new drugs in the market. For instance, in January 2024, Novo Nordisk announced the launch of its Wegovy, a GLP-1 analog in the UK. This drug can be prescribed to people with prediabetes and for weight loss purposes.…
Rapid Test Market Increasing Demand, Growth Analysis and Future Outlook by 2031
The global rapid test market is anticipated to grow at a considerable CAGR of 8.2% during the forecast period (2024-2031). The increasing government initiatives for diagnosing infectious diseases owing to the growing prevalence of infectious diseases and the key developments by the market players. In order to monitor the infection rate of specific pathogens, infection monitoring and surveillance programs have grown over the past few several years. Rapid diagnostic…
AI in Patient Engagement Market Size, Trends, Latest Insights, Analysis and Fore …
Global AI in patient engagement market is anticipated to grow at a CAGR of 21.0 % during the forecast period (2024-2031). AI-powered communication tools support patients by addressing their inquiries, scheduling appointments, and providing information about their health conditions and treatments. These tools enhance patient engagement, improve access to healthcare information, and streamline administrative processes for healthcare providers. Furthermore, AI algorithms analyze large datasets, including electronic health records (EHRs), medical…
More Releases for IBD
Canada Inflammatory Bowel Disease (IBD) Market Size & Growth Analysis Report, 20 …
The Canada IBD market is estimated to grow significantly at a CAGR of around 5.2% during the forecast period. Rising prevalence and incidence of IBD across the country is the major driving factor for the market. Canada has among the highest reported prevalence and incidence rates of IBD across the globe. As per CCC, in 2018, nearly 270,000 Canadians were living with IBD, of which 135,000 individuals with Crohn’s disease,…
Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031
Visiongain has published a new report on Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031: Forecasts by Drug Class (Biologics, Aminosalicylates, Corticosteroids, Antibiotics, Immunomodulators, Others), by Indication (Crohn’s Disease, Ulcerative Colitis), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) AND Regional and Leading National Market Analysis PLUS Analysis of Leading IBD Drug Companies AND COVID-19 Recovery Scenarios.
Global Inflammatory Bowel Disease (IBD) drugs market was valued at US$ US$xx…
US Inflammatory Bowel Disease (IBD) Therapeutics Market Research and Forecast 20 …
The US IBD therapeutics market is estimated to grow significantly at a CAGR of around 4.7% during the forecast period. The factors such as the significant prevalence of IBD such as Crohn’s disease and ulcerative colitis across the country contributing to the market growth. As per the Centers for Disease Control and Prevention (CDC), the prevalence of Crohn’s disease and ulcerative colitis in the US was 201 and 238 per…
France Inflammatory Bowel Disease (IBD) Therapeutics Market Size, Growth and For …
France IBD therapeutics market is estimated to grow significantly at a CAGR of around 4.6% during the forecast period. The growing IBD patient population is one of the major driving forces for the growth of the market in the country. According to the National Institutes of, Health, the total number of cases associated with Crohn's disease in France were registered to be around 72,522 in 2017. This signifies the opportunity…
Global Inflammatory Bowel Disease (IBD) Therapeutics Market, Share, Trends & For …
The global IBD therapeutics market is estimated to grow significantly at a CAGR of around 5.0% during the forecast period. The rise in the number of IBD such as Crohn's disease and ulcerative colitis is augmenting the growth of the global IBD therapeutics market. The increasing prevalence of IBD results in the need for research for the treatment of IBD and innovations in healthcare systems to manage this complex and…
Canada Inflammatory Bowel Disease (IBD) Market Share, Size & Forecast to 2025
The Canada IBD market is estimated to grow significantly at a CAGR of around 5.2% during the forecast period. Rising prevalence and incidence of IBD across the country is the major driving factor for the market. Canada has among the highest reported prevalence and incidence rates of IBD across the globe. As per CCC, in 2018, nearly 270,000 Canadians were living with IBD, of which 135,000 individuals with Crohn's disease,…
